Comparison of clinical efficacy and safety between Alprostadil and regular therapy in treating ischemic stroke: a Meta-analysis / 中华老年医学杂志

ABSTRACT

Objective To evaluate the clinical efficacy and safety between Alprostadil regular therapy in the patients with ischemic stroke. Methods We searched the electronic databases (WANFANG DATA,CNKI,and OVID) in order to obtain the randomized controlled trial (RCT)with interventions of lipo-prostaglandin E1 from January 1,2003 to March 1,2011. The methodological quality of the trials was assessed using four standardsrandom allocation program,allocation concealment,blind and quit.A meta-analysis of included clinical trials was performed with Revman 5.0 software. Results 13 trials were included and the data were divided into 3 groups by different outcomes,the effective rate(12 trials),the neurological deficit score(CCS,6 trials) and the daily life score (4 trials). Meta-analysis showed that after treatment,there were differences in neurological deficit (OR-4.76,95％ CI8.46,-1.06)and daily life(OR0.95,95％ CI-1.52,-0.38) between lipo-PGE1 treatment group and regular treatment group.The effective rate were higher in lipo-PGE1 treatment group than in regular treatment group (OR3.75,95％ CI2.45,5.75).The improvement in the overall symptoms of ischemic stroke after lipo-PGE1 therapy was better than regular treatment.In the occurrence of adverse reactions,18 cases appeared in lipo-PGEl treatment group(among which 11 cases were vascular stimulating reactions after injection),1 case in regular treatment group. Conclusions Lipo-prostaglandin E1 is an effective drug for ischemic stroke in view of its improvements in cure rate,neurological deficit and activities of daily life.